Cart

YOUR CART IS EMPTY

Add research compounds to begin your order.

Peer-reviewed human trials and related publicationsSee approved evidence mapCompleted

Lancet

RET-STUDY-P008

TRANSCEND-T2D-1 investigators. Phase 3 retatrutide in type 2 diabetes. Lancet. 2026. DOI: 10.1016/S0140-6736(26)00967-0. PMID: 42250575. NCT06354660. https://pubmed.ncbi.nlm.nih.gov/42250575/

Study design

Record details

Design: Peer-reviewed human trials and related publications

Evidence record

Endpoints, findings, and limitations

Limitations

This study record is an evidence-index entry. Interpret the design, material, population or model, endpoints, findings, and limitations only within the linked approved source and compound evidence map; do not transfer outcomes across compounds, materials, cohorts, or models.

Reports and sources

Reference ledger

P008Peer-reviewed human trials and related publications

Lancet

TRANSCEND-T2D-1 investigators. Phase 3 retatrutide in type 2 diabetes. TRANSCEND-T2D-1 investigators. Phase 3 retatrutide in type 2 diabetes. Lancet. 2026. DOI: 10.1016/S0140-6736(26)00967-0. PMID: 42250575. NCT06354660. https://pubmed.ncbi.nlm.nih.gov/42250575/(2026). DOI: 10.1016/S0140-6736(26